Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SPERO THERAPEUTICS, INC.

(SPRO)
  Rapport
Vertraagde tijd Nasdaq  -  22:00:00 02-02-2023
1.830 USD   -2.66%
01/02Spero Therapeutics, Inc. Benoemt Timothy Keutzer tot Chief Operating Officer, met ingang van 1 februari 2023
CI
2022Transcript : Spero Therapeutics, Inc., Q3 2022 Earnings Call, Nov 14, 2022
CI
2022Spero Therapeutics, Inc. rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2022
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op SPERO THERAPEUTICS, INC.
01/02Spero Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
01/02Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective..
31/01Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01Spero Therapeutics, Inc. : Results of Operations and Financial Condition, Regulation FD Di..
2022Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from N..
2022Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
2022Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $2M
2022SPERO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
2022Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business..
2022Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
2022Spero Therapeutics Closes License Deal With GSK for Investigational Drug for Urinary Tr..
2022Spero Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
2022Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipe..
2022Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipe..
2022Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding fr..
2022Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial R..
2022Spero Therapeutics to Present Data at IDWeek 2022
2022Spero Therapeutics to Present Data at IDWeek 2022
2022Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary..
2022North American Morning Briefing: Stock Futures -2-
2022GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a la..
2022USA-Les valeurs à suivre à Wall Street (actualisé)
2022ADRs End Mostly Lower; Compagnie de Saint-Gobain Trades Actively
2022Sector Update: Health Care Stocks Gain Thursday Afternoon
2022Sector Update: Health Care
2022Top Midday Gainers
2022Global markets live: Veolia, Meta, Amazon, Salesforce, Target...
2022Fed up!
2022Sector Update: Health Care Stocks Mixed Premarket Thursday
2022Sector Update: Health Care
2022BOE Raises rates Again, Cuts Inflation Expectations
2022Spero Therapeutics Shares Take Flight Premarket on GSK Pact
2022Pound Rises Before Likely BOE Rate Rise But Seen Vulnerable
2022FTSE 100 Drops Ahead of BOE; Weak Earnings Hit JD Sports
2022Spero Therapeutics, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale o..
2022GSK : accord de licence avec Spero Therapeutics
2022US Stock Futures Trend Lower Following Fed Rate Increase of 75 Basis Points
2022Top Premarket Gainers
2022GSK plc and Spero Therapeutics, Inc. Announce Exclusive Licence Agreement for Tebipenem..
2022UK Poorly Positioned to Cope With Rising Interest Rates
2022GSK Receives Exclusive License for Spero Therapeutics' Oral Antibiotic Candidate
2022GSK eyes Spero's experimental urinary tract infection drug, takes stake
2022FTSE 100 to Tumble After Heavy U.S. Losses, Fed Hike
2022GSK takes stake in Spero in deal for experimental UTI treatment
2022GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiot..
2022GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiot..
2022GSK Secures Urinary Tract Infections Treatment License With Spero Therapeutics
2022Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in fund..
2022Spero Therapeutics, Inc. : Change in Directors or Principal Officers, Submission of Matter..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from S..
2022Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical..
2022Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer
2022Spero Therapeutics to Present at Upcoming Investor Conference
2022Spero Therapeutics Shares Up 38% On FDA's Feedback of Tebipenem HBr Program
2022Spero Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
2022Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with ..
2022Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with ..
2022Spero Therapeutics : Announces Second Quarter 2022 Operating Results and Provides Business..
2022Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q2 Revenue $2M
2022SPERO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
2022Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Busines..
2022Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months..
2022Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial ..
2022Spero Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
2022Spero Therapeutics : Receives Complete Response Letter from U.S. Food and Drug Administrat..
2022Spero Therapeutics Sinks After-Hours as FDA Rejects Tebipenem HBr New Drug Application
2022Spero Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
2022Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug ..
2022Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administra..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from R..
2022Spero Therapeutics, Inc. : Termination of a Material Definitive Agreement, Financial State..
2022Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q1 Revenue $2.1M, vs. Street Est of $1.9..
2022SPERO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
2022Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business..
2022Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
2022Spero Therapeutics to Present at Upcoming Investor Conferences
2022Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial R..
2022Top Midday Decliners
2022Spero Therapeutics Shares Drop 66%, Hit 52-Week Low
2022Spero Therapeutics Cuts 75% Workforce, Ends Urinary Tract Infection Drug; Shares Sink
2022Wall Street Set for Small Gains Ahead of Fed Meeting
2022Top Premarket Decliners
2022Spero Therapeutics, Inc. : Costs Associated with Exit or Disposal Activities, Change in Di..
Volgende evenement op SPERO THERAPEUTICS, INC.